| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA764: Fremanezumab for preventing migraine |
|
Medicine details |
|
| Medicine name | fremanezumab (Ajovy®) |
| Formulation | 225 mg solution for injection |
| Reference number | 3013 |
| Indication | Prophylaxis of migraine in adults who have at least 4 migraine days per month |
| Company | TEVA UK Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/03/2019 |
| NICE guidance | |
| Commercial arrangement | PAS |